X4 Pharmaceuticals

124 articles with X4 Pharmaceuticals

• X4 Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results and Provide Recent Business Highlights on March 12, 2020

  2/27/2020

  X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), today announced it will host a conference call and webcast to report its financial results for the fourth quarter and full year ended December 31, 2019 on March 12, 2020 at 8:30 a.m. ET. The conference call can be accessed by dialing (866) 721-765

• X4 Pharmaceuticals to Present at Two Upcoming Investor Conferences in March

  2/25/2020

  Feb. 25, 2020 13:30 UTC X4 Pharmaceuticals to Present at Two Upcoming Investor Conferences in March CAMBRIDGE, Mass.--( BUSINESS WIRE )-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced that the management team will present and conduct one-on-one meetings at Cowen and Company’s 40th Annual Health Care Conference and Oppenheimer's 30th Annual H

• X4 Pharmaceuticals Granted New Composition of Matter Patent for Late-Stage Clinical Candidate Mavorixafor

  2/12/2020

  Feb. 12, 2020 13:00 UTC – Patent expected to provide exclusivity through 2038 – CAMBRIDGE, Mass.--( BUSINESS WIRE )-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued United States Patent No. 10,548,889, which is expected to provide exclusivity of X4’s lead therapeuti

• 

  Clinical Catch-Up: December 30, 2019 – January 2, 2020

  1/6/2020

  Even with the holiday week, there was still some clinical trial news coming out. Here’s a look.

• X4 Pharmaceuticals Initiates Phase 1b Clinical Trial of Mavorixafor in Combination with Ibrutinib for the Treatment of Waldenström’s Macroglobulinemia (WM)

  12/30/2019

  Trial to assess safety and tolerability of mavorixafor in combination with ibrutinib in WM patients with MYD88/CXCR4 double mutation associated with treatment resistance

• X4 Pharmaceuticals Prices $65 Million Public Offering of Common Stock and Class B Warrants

  11/26/2019

  X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics for the treatment of rare diseases, announced today the pricing of its previously announced underwritten public offering of 3,666,667 shares of its common stock and, in lieu of common stock, pre-funded warrants to purchase 1,750,000 shares of common stock

• X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 26, 2019

  11/26/2019

  X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, announced that, on November 26, 2019, the Compensation Committee of X4’s Board of Directors issued an inducement award to a new employee under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.

• X4 Pharmaceuticals Announces Proposed Public Offering

  11/25/2019

  X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics for the treatment of rare diseases, announced today that it has commenced an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof) and Class B warrants to purchase its common stock

• X4 Pharmaceuticals to Present at Stifel 2019 Healthcare Conference

  11/15/2019

  X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced that management will present at the Stifel 2019 Healthcare Conference on Tuesday, November 19th, 2019 at 8:35 am EST in New York, NY.

• X4 Pharmaceuticals Receives Breakthrough Therapy Designation from the FDA for Mavorixafor for the Treatment of WHIM Syndrome

  11/12/2019

  Mavorixafor is a potential first-in-class, once-daily, oral, small molecule antagonist of chemokine receptor CXCR4, and is currently being investigated in a pivotal Phase 3 global clinical trial, 4WHIM, for the treatment of WHIM syndrome.

• 

  BioSpace Movers & Shakers, Nov. 8

  11/8/2019

  Pharmaceutical, medtech and biotech companies expand their leadership teams with this week's appointments.

• X4 Pharmaceuticals Reports Third Quarter 2019 Financial Results and Recent Business Highlights

  11/7/2019

  Reported positive data from Phase 2a clinical trial of mavorixafor in combination with axitinib in advanced clear cell renal cell carcinoma patients

• X4 Pharmaceuticals Initiates Phase 1b Clinical Trial of Mavorixafor for the Treatment of Severe Congenital Neutropenia

  11/5/2019

  X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the initiation of a Phase 1b clinical trial of mavorixafor (X4P-001) for the treatment of Severe Congenital Neutropenia (SCN), a group of rare blood disorders characterized by abnormally low levels of neutrophils.

• X4 Pharmaceuticals Appoints Derek Meisner, J.D., as General Counsel

  11/4/2019

  Mr. Meisner brings more than two decades of experience providing counsel to public and private companies across key legal and operational functions, including regulatory compliance, debt and equity financings, mergers and acquisitions, strategic partnerships and corporate governance.

• X4 Pharmaceuticals to Announce Third Quarter 2019 Financial Results and Provide Recent Business Highlights on November 7, 2019

  10/25/2019

  X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced that it will report its financial results for the third quarter ended September 30, 2019 before market open on Thursday, November 7, 2019.

• X4 Pharmaceuticals Reports Positive Data from Phase 2a Trial of Mavorixafor in Combination with Axitinib in Advanced Clear Cell Renal Cell Carcinoma Patients

  9/30/2019

  X4 Pharmaceuticals, Inc. announced positive results from the Phase 2a portion of its open-label Phase 1/2 clinical trial of mavorixafor in combination with axitinib in patients with advanced clear cell renal cell carcinoma.

• X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sept. 27, 2019

  9/27/2019

  X4 Pharmaceuticals, Inc. announced that, on September 27, 2019, the Compensation Committee of X4’s Board of Directors issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.

• 

  BioSpace Movers & Shakers, Sept. 27

  9/27/2019

  Biotech and pharma companies strengthen their leadership teams and boards of directors with this week's appointments.

• X4 Pharmaceuticals Appoints William E. Aliski to Board of Directors

  9/23/2019

  Mr. Aliski has more than two decades of biopharmaceutical executive leadership experience at both public and private companies

• 

  BioSpace Movers & Shakers, Sept. 20

  9/20/2019

  Biotech and pharma companies from across the globe strengthen their leadership teams and boards of directors with this week's appointments.